| A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS (NCT00000688) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination (NCT00006153) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) Infection (NCT00005572) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of d4T in Patients With AIDS or AIDS-Related Complex Who Cannot Take AZT (NCT00000686) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults (NCT00043511) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009) (NCT00001021) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART) (NCT00076518) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies (NCT00000869) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo) (NCT00001041) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Tolerability of the Vaginal Gel PRO 2000/5 (NCT00006207) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Test the Safety of Three Experimental HIV Vaccines (NCT00000946) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers (NCT00000847) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine (NCT00000835) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants (NCT00000944) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Optimal Treatment for Kidney Disease in HIV Infected Adults (NCT00089518) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination (NCT00006291) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers (NCT00000774) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects (NCT00000882) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients (NCT00001094) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients (NCT00013585) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir (NCT00000985) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex (NCT00000710) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component (NCT00000665) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children (NCT00000637) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) (NCT00000836) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients (NCT00000991) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy (NCT00000820) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex (NCT00000986) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy (NCT00050271) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of Adefovir Dipivoxil in HIV-Infected Children (NCT00000843) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Study of a Flu Vaccine in Children (NCT00001127) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months (NCT00000749) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| SARS Survivor Evaluations (NCT00523276) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex (NCT00000976) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients. (NCT00000796) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children (NCT00000851) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effect of Acyclovir Treatment of the Herpes Simplex Virus (HSV) Infection on HIV Levels in the Blood (NCT00001115) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV (NCT00000791) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex (NCT00000657) | National Institute of Allergy and Infectious Diseases (NIAID) | |